GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Insight Molecular Diagnostics Inc (NAS:IMDX) » Definitions » Beneish M-Score

IMDX (Insight Molecular Diagnostics) Beneish M-Score : 4.96 (As of Jul. 04, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Insight Molecular Diagnostics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 4.96 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Insight Molecular Diagnostics's Beneish M-Score or its related term are showing as below:

IMDX' s Beneish M-Score Range Over the Past 10 Years
Min: -21.78   Med: -0.05   Max: 155.37
Current: 4.96

During the past 12 years, the highest Beneish M-Score of Insight Molecular Diagnostics was 155.37. The lowest was -21.78. And the median was -0.05.


Insight Molecular Diagnostics Beneish M-Score Historical Data

The historical data trend for Insight Molecular Diagnostics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Insight Molecular Diagnostics Beneish M-Score Chart

Insight Molecular Diagnostics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.16 -21.78 -3.15 -1.73

Insight Molecular Diagnostics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.82 -4.06 0.16 -1.73 4.96

Competitive Comparison of Insight Molecular Diagnostics's Beneish M-Score

For the Diagnostics & Research subindustry, Insight Molecular Diagnostics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Insight Molecular Diagnostics's Beneish M-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Insight Molecular Diagnostics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Insight Molecular Diagnostics's Beneish M-Score falls into.


;
;

Insight Molecular Diagnostics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Insight Molecular Diagnostics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 7.907+0.528 * 0.6167+0.404 * 0.3393+0.892 * 2.7808+0.115 * 1.0951
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.41+4.679 * -0.012227-0.327 * 1.2752
=4.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar25) TTM:Last Year (Mar24) TTM:
Total Receivables was $3.54 Mil.
Revenue was 2.138 + 1.486 + 0.115 + 0.104 = $3.84 Mil.
Gross Profit was 1.325 + 0.595 + 0.05 + 0.05 = $2.02 Mil.
Total Current Assets was $36.26 Mil.
Total Assets was $60.36 Mil.
Property, Plant and Equipment(Net PPE) was $7.16 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.72 Mil.
Selling, General, & Admin. Expense(SGA) was $14.41 Mil.
Total Current Liabilities was $9.68 Mil.
Long-Term Debt & Capital Lease Obligation was $2.07 Mil.
Net Income was -6.671 + -33.511 + -13.493 + -4.53 = $-58.21 Mil.
Non Operating Income was -0.722 + -28.058 + -7.087 + 1.141 = $-34.73 Mil.
Cash Flow from Operations was -5.858 + -5.354 + -5.551 + -5.978 = $-22.74 Mil.
Total Receivables was $0.16 Mil.
Revenue was 0.176 + 0.314 + 0.429 + 0.463 = $1.38 Mil.
Gross Profit was 0.045 + -0.117 + 0.248 + 0.272 = $0.45 Mil.
Total Current Assets was $6.54 Mil.
Total Assets was $70.97 Mil.
Property, Plant and Equipment(Net PPE) was $5.73 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.54 Mil.
Selling, General, & Admin. Expense(SGA) was $12.64 Mil.
Total Current Liabilities was $8.33 Mil.
Long-Term Debt & Capital Lease Obligation was $2.51 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(3.54 / 3.843) / (0.161 / 1.382)
=0.921155 / 0.116498
=7.907

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0.448 / 1.382) / (2.02 / 3.843)
=0.324168 / 0.525631
=0.6167

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (36.263 + 7.155) / 60.36) / (1 - (6.535 + 5.727) / 70.973)
=0.280683 / 0.82723
=0.3393

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=3.843 / 1.382
=2.7808

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.543 / (1.543 + 5.727)) / (1.72 / (1.72 + 7.155))
=0.212242 / 0.193803
=1.0951

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(14.407 / 3.843) / (12.638 / 1.382)
=3.748894 / 9.144718
=0.41

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((2.074 + 9.683) / 60.36) / ((2.514 + 8.327) / 70.973)
=0.194781 / 0.152748
=1.2752

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-58.205 - -34.726 - -22.741) / 60.36
=-0.012227

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Insight Molecular Diagnostics has a M-score of 4.96 signals that the company is likely to be a manipulator.


Insight Molecular Diagnostics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Insight Molecular Diagnostics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Insight Molecular Diagnostics Business Description

Traded in Other Exchanges
Address
15 Cushing, Irvine, CA, USA, 92618
OncoCyte Corp is a pioneering diagnostics technology company. Its mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers, or payers.
Executives
Broadwood Partners Lp 10 percent owner BROADWOOD CAPITAL INC., 142 WEST 57TH STREET, 11TH FLOOR, NEW YORK NY 10019
Andrew Arno director C/O MERRIMAN CURHAN FORD GROUP, INC., 600 CALIFORNIA STREET, 9TH FLOOR, SAN FRANCISCO CA 94108
Josh Riggs officer: Interim CEO 15 CUSHING, IRVINE CA 92618
John Peter Gutfreund other: Former Director 767 5TH AVENUE, 44TH FLOOR, NEW YORK NY 10153
Alfred D Kingsley director 150 E 57TH STREET, NEW YORK NY 10022
Pura Vida Investments, Llc 10 percent owner 512 W 22ND STREET, 7TH FLOOR, NEW YORK NY 10011
Lou Silverman director
James Yang Liu officer: Controller, PAO C/O ONCOCYTE CORPORATION, 15 CUSHING, IRVINE CA 92618
Andrew J. Last director 3420 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051
Jennifer L. Carter director C/O DFP SPONSOR LLC, 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Ronald Asbury Andrews director 5791 VAN ALLEN WAY, CARLSBAD CA 92008
Melinda Griffith director 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Anish M. John officer: SVP, Finance, and Interim CFO C/O ONCOCYTE CORPORATION,, 15 CUSHING, IRVINE CA 92618
Li Yu officer: VP Cntrllr/Prncpl Acctng Offcr 120 NEWPORT CENTER DRIVE., NEWPORT BEACH CA 92660
Efrem Kamen 10 percent owner C/O PURA VIDA INVESTMENTS, LLC, 512 W 22ND STREET, 7TH FLOOR, NEW YORK NY 10011